Schoolcraft Memorial Hospital launches Pluvicto therapy, first in Upper Peninsula
MANISTIQUE, MI. — May 18, 2026 - Schoolcraft Memorial Hospital, in collaboration with Green Bay Oncology, has launched a new Nuclear Medicine service line offering Pluvicto (lutetium Lu-177 vipivotide tetraxetan), an FDA-approved targeted therapy for patients with advanced metastatic prostate cancer. With this addition, Schoolcraft Memorial Hospital is the only provider in Michigan’s Upper Peninsula offering this highly specialized treatment, bringing advanced cancer care closer to home. “Establishing a Nuclear Medicine Therapy Clinic with Schoolcraft Memorial Hospital and ...